Celsius Holdings, Inc. (NASDAQ:CELH – Free Report) – Research analysts at B. Riley cut their Q3 2024 earnings estimates for Celsius in a research report issued to clients and investors on Sunday, November 3rd. B. Riley analyst J. Van. Sinderen now anticipates that the company will post earnings of $0.02 per share for the quarter, down from their prior estimate of $0.07. B. Riley currently has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for Celsius’ current full-year earnings is $0.79 per share. B. Riley also issued estimates for Celsius’ FY2024 earnings at $0.65 EPS, FY2025 earnings at $0.71 EPS and FY2026 earnings at $1.09 EPS.
Celsius (NASDAQ:CELH – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.23 by $0.05. Celsius had a net margin of 19.58% and a return on equity of 94.75%. The company had revenue of $402.00 million during the quarter, compared to analysts’ expectations of $391.07 million. During the same quarter in the previous year, the business posted $0.17 EPS. The firm’s revenue was up 23.4% on a year-over-year basis.
Check Out Our Latest Analysis on Celsius
Celsius Stock Down 1.3 %
NASDAQ CELH opened at $31.07 on Tuesday. The stock has a market capitalization of $7.24 billion, a PE ratio of 30.56, a price-to-earnings-growth ratio of 2.34 and a beta of 1.86. Celsius has a 52 week low of $28.20 and a 52 week high of $99.62. The firm has a 50 day moving average of $32.81 and a two-hundred day moving average of $52.06.
Insiders Place Their Bets
In other Celsius news, CEO John Fieldly sold 74,847 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $32.80, for a total transaction of $2,454,981.60. Following the completion of the transaction, the chief executive officer now owns 1,812,490 shares in the company, valued at approximately $59,449,672. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.20% of the stock is owned by insiders.
Hedge Funds Weigh In On Celsius
Large investors have recently bought and sold shares of the company. Venturi Wealth Management LLC acquired a new position in shares of Celsius during the 3rd quarter worth $55,000. Crossmark Global Holdings Inc. grew its stake in shares of Celsius by 8.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 10,723 shares of the company’s stock worth $336,000 after purchasing an additional 834 shares during the period. Covestor Ltd grew its stake in shares of Celsius by 35.4% during the 3rd quarter. Covestor Ltd now owns 5,978 shares of the company’s stock worth $187,000 after purchasing an additional 1,564 shares during the period. Bridges Investment Management Inc. grew its stake in shares of Celsius by 15.0% during the 3rd quarter. Bridges Investment Management Inc. now owns 16,783 shares of the company’s stock worth $526,000 after purchasing an additional 2,186 shares during the period. Finally, CWA Asset Management Group LLC acquired a new position in shares of Celsius during the 3rd quarter worth $5,700,000. Hedge funds and other institutional investors own 60.95% of the company’s stock.
About Celsius
Celsius Holdings, Inc develops, processes, markets, distributes, and sells functional energy drinks and liquid supplements in the United States, Australia, New Zealand, Canadian, European, Middle Eastern, Asia-Pacific, and internationally. The company offers CELSIUS, a fitness drink or supplement designed to accelerate metabolism and burn body fat; various flavors and carbonated and non-carbonated functional energy drinks under the CELSIUS Originals and Vibe name, as well as functional energy drink under the CELSIUS Essentials and CELSIUS On-the-Go Powder names; and CELSIUS ready-to drink products.
See Also
- Five stocks we like better than Celsius
- What is the S&P 500 and How It is Distinct from Other Indexes
- Intel: Is Now the Time to Be Brave?Â
- What Does Downgrade Mean in Investing?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Special Dividend?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Celsius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsius and related companies with MarketBeat.com's FREE daily email newsletter.